Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Efficacy and Tolerability of Subcutaneously Administered Treprostinil Sodium in Patients With Severe (Non-operable) Chronic Thromboembolic Pulmonary Hypertension (CTREPH) (CTREPH)

17. Mai 2022 aktualisiert von: SciPharm SàRL

A Double Blind Controlled Clinical Study to Investigate the Efficacy and Tolerability of Subcutaneous Treprostinil Sodium in Patients With Severe Non-operable Chronic Thromboembolic Pulmonary Hypertension (CTREPH)

The primary purpose of this study is to determine the effect on six-minute walking test (6MWT) distance after 24 weeks treatment with subcutaneous (SC) Treprostinil Sodium in patients with Severe (inoperable) Chronic Thromboembolic Pulmonary Hypertension.

Studienübersicht

Status

Abgeschlossen

Bedingungen

Intervention / Behandlung

Detaillierte Beschreibung

Chronic thromboembolic pulmonary hypertension (CTEPH) is characterized by non-resolving organized thromboembolic obstructing the pulmonary vascular bed. These thrombi are resistant to thrombolytic therapy and chronic plasmatic anticoagulation. An increase in pulmonary vascular resistance (PVR), right ventricular overload, and eventually right ventricular failure ensue.

The treatment of choice for CTEPH is pulmonary endarterectomy (PEA), providing a potential cure for the disease. However, about 50 % of patients are not candidates for surgery, mainly because of distal location of thromboemboli. Despite recent advances in the treatment of pulmonary arterial hypertension (PAH), medical treatments have not been recommended for inoperable CTEPH, because of the concept that a predominantly major vessel obstructive arteriopathy would not be suitable for vasodilators. Furthermore, a major drawback of i.v. prostacyclin therapy is the need for a permanent central venous access that increases the risk of infection (0.22-0.68 per patient per year), thrombosis and new major vessel thromboembolism.

Studientyp

Interventionell

Einschreibung (Tatsächlich)

105

Phase

  • Phase 3

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienorte

  • Deutschland
      • Dresden, Deutschland
        • Medical University Carl Gustav Carus Medizinische Klinik und Poliklinik I Medizinische Fakultät der Technischen Universität Dresden
  • Polen
      • Krakow, Polen, 31-202
        • Department of Cardiac and Vascular Diseases Centre for Rare Cardiovascular Diseases John Paul II Hospital
      • Otwock, Polen, 05-400
        • NZOZ Europejskie Centrum Zdrowia Otwock
  • Tschechien
      • Prague, Tschechien
        • II. interní klinika Všeobecná fakultní nemocnice
  • Österreich
      • Linz, Österreich, 4020
        • Krankenhaus der Elisabethinen
      • Vienna, Österreich
        • Medical University of Vienna AKH - Division Cardiology

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

18 Jahre bis 100 Jahre (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Beschreibung

  1. Subject must be competent to understand the information given in the written informed consent and from the investigator and must sign and date the informed consent prior to any study mandated procedure.
  2. Subject must be at least 18 years of age and can be of any ethnical origin
  3. Women of child bearing potential must be surgically sterile or postmenopausal (amenorrhea for at least 12 months) or using an acceptable form of contraception. Reliable contraception is defined as a method which results in a low failure rate, i.e., less than 1% per year when used correctly such as, implants, injectables, oral contraceptive medications, sexual abstinence, or a vasectomised partner.

  4. Subject must have a current diagnosis of CTEPH, as defined by the following criteria:

    • A test result of perfusion scintigraphy and pulmonary angiography and/or multislice CT not older than 6 months, consistent with the diagnosis CTEPH. In case of recurrent PH after PEA, test results from before the surgery are acceptable if a typical specimen was harvested during PEA substantiating the diagnosis of CTEPH.
    • A right heart catheterization, not older than 6 months, consistent with the diagnosis CTEPH but specifically with a mean pulmonary artery pressure (PAPm) of > 25 mmHg, and a PVR of > 300 dyn.s.cm-5
    • At least three months of effective anticoagulation therapy (without improvement / to exclude subacute pulmonary emboli)

  5. Subject must have CTEPH classified as severe, as defined by the following criteria:

    • An un-encouraged 6MWT distance of between 150 and 400 meters
    • Classification in the WHO/New York Heart Association (NYHA) functional class III or IV

  6. The subject must not be suitable to undergo a PEA and is therefore defined as non-operable, due to at least one of the following reasons:

    • Clot is not accessible
    • Discrepancy between severity of PH and morphologic lesion
    • Subject is not a good surgical candidate for other reasons:

    PVR > 1500 dynes.s.cm-5 Age Comorbidity No functional lung parenchyma

    • Unsuccessful PEA in the past with residual/recurrent CTEPH
    • No consent for PEA given by subject
  7. Subject must be willing and able to follow all study procedures

Exclusion:

  1. Subject with any form of pulmonary arterial hypertension or any disease known to cause PAH (WHO Group I)
  2. Subjects with a total lung capacity (TLC) of < 70% predicted or a forced expiratory volume/forced vital capacity (FEV1/FVC < 50%)
  3. Subject who received any prostanoids, within the 30 days before screening or be scheduled to receive prostanoids during the course of the study
  4. Subject with a new type of chronic therapy (a different category of vasodilator or diuretic) for PAH added within the last month, except anticoagulants
  5. Subject with an increased risk for hemorrhage or stroke or with a major cardiovascular event during the past 6 months.
  6. Unstable subjects for any reason (according to the investigators discretion)
  7. Subject who received any investigational medication within 30 days prior to the screening visit of this study or be scheduled to receive another investigational drug during the course of this study
  8. Subject with a known intolerance to any drug relevant for this trial, especially to Treprostinil sodium or prostanoids
  9. Subject with a history or suspicion of non compliance
  10. Subject who has any musculoskeletal disease or any other disease that would limit ambulation
  11. Subject with other cardiovascular, liver, renal, hematologic, gastrointestinal immunologic, endocrine, metabolic, or central nervous system disease that, in the opinion of the investigator, may adversely affect the safety of the subject and /or efficacy of the study drug or limit the lifespan of the subject
  12. Female who is considering pregnancy or who is pregnant and/or lactating
  13. Subject who is an investigator or any other team member involved directly or indirectly in the conduct of the clinical study.
  14. Subject who is an inmate of a psychiatric ward, prison or is suspected not to be able to give consent of his free will

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Behandlung
  • Zuteilung: Zufällig
  • Interventionsmodell: Parallele Zuordnung
  • Maskierung: Vervierfachen

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Aktiver Komparator: Treprostinil sodium low dose - Arm I

Arm I (low dose):

Subject was treated with a low dose of Treprostinil sodium. Dose was escalated to an approximate target dose of 3 ng/kg/min after the first 12 weeks and was kept stable for another 12 weeks.

Due to the predefined infusion rate setting schedule an interim dose of up to 6 ng/kg/min could be reached for few days at the end of the phases 1,2 and 3.

This depended on the patient's exact weight and is caused by the limited infusion rate setting possibility of the infusion pump.
Arzneimittel: Treprostinil sodium
Experimental: Treprostinil sodium high dose - Arm II

Subject was treated with a low dose of Treprostinil sodium. Dose was escalated to an approximate target dose of 3 ng/kg/min after the first 12 weeks and kept stable for another 12 weeks.

Due to the predefined infusion rate setting schedule an interim dose of up to 6 ng/kg/min could be reached for few days at the end of the phases 1,2 and 3.

This depended on the patient's exact weight and is caused by the limited infusion rate setting possibility of the infusion pump.
Arzneimittel: Treprostinil sodium

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Change in 6-minute Walk Test Distance After 24 Weeks
Zeitfenster: Baseline and 24 weeks

To determine the effect of subcutaneous Treprostinil sodium on 6-minute walk test distance after 24 weeks in patients with severe non-operable chronic thromboembolic pulmonary hypertension severe (inoperable) Chronic Thromboembolic Pulmonary Hypertension

Time frame of the 6-minute walk test: The 6-minute walk test was conducted at the following visits:

  • baseline (day 1)
  • Visit 6 (day 168)

In case of missing values, Last-Observation-Carried-Forward imputation method was used. In such cases values documented at Visit 4 (day84) were used.
Baseline and 24 weeks

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Number of Participants With Clinical Worsening
Zeitfenster: 12 weeks and 24 weeks

Clinical worsening defined as a decrease of 6-minute walk test distance of more than 20% from baseline due to Chronic Thromboembolic Pulmonary Hypertension, decrease of New York Heart Association functional class, hospitalization with the requirement for additional Pulmonary Hypertension specific treatment and/or death due to worsening Chronic Thromboembolic Pulmonary Hypertension.

Clinical Worsening was assessed after 12 weeks and 24 weeks, participants experiencing clinical worsening at any time-point are reported.
12 weeks and 24 weeks
Effect on Maximal Borg Score During 6-minutes Walk Test
Zeitfenster: Baseline and 24 weeks

The Borg scale was used for rating of dyspnea during 6-minutes walk test. The scale is defined from 0 to > 10 (upper bound) (0 = NOTHING AT ALL; 0.5 = VERY VERY SLIGHT (just noticeable); 1 = VERY SLIGHT; 2 = SLIGHT; 3 = MODERATE; 4 = SOMEWHAT SEVERE; 5 = SEVERE; 6-9 = VERY SEVERE; 10 = VERY VERY SEVERE (almost maximum); >10 MAXIMUM).

As can be seen with the scale, the higher scale values represent a worse outcome.

As no imputation rule applied only full-data sets were evaluated. Complete data sets were available for 48 patients randomized to high dose group and 48 patients in low dose group.
Baseline and 24 weeks
Change in WHO/NYHA (World Health Organization - New York Heart Association) Functional Class
Zeitfenster: Baseline and 24 weeks

Class I - Patients with pulmonary hypertension but without resulting limitation of physical activity. Ordinary physical activity does not cause undue dyspnea or fatigue, chest pain or near syncope.

Class II - Patients with pulmonary hypertension resulting in slight limitation of physical activity. They are comfortable at rest. Ordinary physical activity causes undue dyspnea or fatigue, chest pain or near syncope.

Class III - Patients with pulmonary hypertension resulting in marked limitation of physical activity. They are comfortable at rest. Less than ordinary activity causes undue dyspnea or fatigue, chest pain or near syncope

Class IV - Patients with pulmonary hypertension in the inability to carry out any physical activity without symptoms. These patients manifest signs of right heart failure. Dyspnea and/or fatigue may even be present at rest. Discomfort is increased by any physical activity.
Baseline and 24 weeks
Effect on Quality of Life by the MINNESOTA Questionnaire
Zeitfenster: Baseline and 24 weeks

This questionnaire is composed of 21 questions relating to limitations in lifestyle associated with Heart Failure. Respondents use a 5-point scale that ranges from 0 (none) to 5 (too much), with a score of 0 representing no limitation and a score of 5 representing maximum limitation. The change in individual score sum was evaluated and is displayed in the results, with a possible range of 0-105. Higher values indicate more limitations in Quality of Life.

As no imputation rule applied only full-data sets were evaluated. Complete data sets were available for 50 patients randomized to high dose group and 46 patients in low dose group.
Baseline and 24 weeks
Effect on N-terminal Pro-BNP Levels
Zeitfenster: Baseline and 24 weeks

baseline values, assessment after 12 and 24 weeks

As no imputation rule applied only full-data sets were evaluated. Complete data sets were available for 46 patients randomized to high dose group and 46 patients in low dose group.
Baseline and 24 weeks
Effect on Hemodynamic Parameter (PVR - Pulmonary Vascular Resistance)
Zeitfenster: Baseline and 24 weeks

baseline values, assessment after 24 weeks

As no imputation rule applied only full-data sets were evaluated. Complete data sets were available for 48 patients randomized to high dose group and 47 patients in low dose group.
Baseline and 24 weeks
Effect on Hemodynamic Parameter (CI - Cardiac Index)
Zeitfenster: Baseline and 24 weeks

baseline values, assessment after 24 weeks

As no imputation rule applied only full-data sets were evaluated. Complete data sets were available for 48 patients randomized to high dose group and 47 patients in low dose group.
Baseline and 24 weeks
Effect on Hemodynamic Parameter (CO - Cardiac Output)
Zeitfenster: Baseline and 24 weeks

baseline values, assessment after 24 weeks

As no imputation rule applied only full-data sets were evaluated. Complete data sets were available for 48 patients randomized to high dose group and 47 patients in low dose group.
Baseline and 24 weeks
Effect on Hemodynamic Parameter (mPAP - Mean Pulmonary Arterial Pressure)
Zeitfenster: Baseline and 24 weeks

baseline values, assessment after 24 weeks

As no imputation rule applied only full-data sets were evaluated. Complete data sets were available for 47 patients randomized to high dose group and 47 patients in low dose group.
Baseline and 24 weeks
Effect on Hemodynamic Parameter (mRap - Mean Right Atrial Pressure)
Zeitfenster: Baseline and 24 weeks

baseline values, assessment after 24 weeks

As no imputation rule applied only full-data sets were evaluated. Complete data sets were available for 48 patients randomized to high dose group and 47 patients in low dose group.
Baseline and 24 weeks
Effect on Signs & Symptoms of the CTEPH
Zeitfenster: Baseline and 24 weeks
baseline values, assessment after 24 weeks
Baseline and 24 weeks

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

SciPharm SàRL

Ermittler

  • Hauptermittler: Irene Lang, MD, Medical University Vienna

Publikationen und hilfreiche Links

Die Bereitstellung dieser Publikationen erfolgt freiwillig durch die für die Eingabe von Informationen über die Studie verantwortliche Person. Diese können sich auf alles beziehen, was mit dem Studium zu tun hat.

Allgemeine Veröffentlichungen

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn

1. März 2009

Primärer Abschluss (Tatsächlich)

1. November 2016

Studienabschluss (Tatsächlich)

1. April 2021

Studienanmeldedaten

Zuerst eingereicht

12. August 2011

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

12. August 2011

Zuerst gepostet (Schätzen)

15. August 2011

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

7. Juni 2022

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

17. Mai 2022

Zuletzt verifiziert

1. Mai 2022

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Zusätzliche relevante MeSH-Bedingungen

Andere Studien-ID-Nummern

  • 116-02

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Klinische Studien zur Treprostinil sodium

Suchen Sie nach ähnlichen Studien

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

CROs by country

CROs in Panama

Bedingungen

Seltene Krankheiten

Drogeninterventionen

Nahrungsergänzungsmittel

Sponsor / Mitarbeiter

Standorte

3
Abonnieren